Improved overall survival with abemaciclib in early breast cancer
Adjiuvant abemaciclib added to endocrine therapy improves overall survival in patients with HR+/HER2- high risk early breast cancer
Day: December 10, 2025
Adjiuvant abemaciclib added to endocrine therapy improves overall survival in patients with HR+/HER2- high risk early breast cancer